Abstract
Among neurodegenerative diseases, “What kind of disease should we know now?” is the theme given to me at the 38th Annual Meeting of the Japanese Society of Neurological Therapeutics. In recent years, neuroimaging have been actively incorporated as objective biomarkers into diagnostic criteria for neurodegenerative diseases, and there are a wide variety of issues to be addressed. In this paper, in the limited space, the characteristic MRI findings of diffusion–enhanced images trigger the diagnosis of intranuclear inclusion disease, hereditary diffuse leukoencephalopathy with axonal spheroids–CSF1R and their differential diagnoses. In addition, as the development of Alzheimer's disease modifiers progresses, it is important to distinguish diseases other than Alzheimer's disease, which develop due to forgetfulness and show the first imaging findings of hippocampal atrophy. I will describe argyrophilic grain disease/dementia of grains (AGD/DG), primary age–related tauopathy (PART), limbic–predominant age–related TDP–43 encephalopathy (LATE) and their differential diagnoses, and hope that it would be a useful step for the treatment of neurodegenerative diseases in the near future.
